Induction of Fatigue by Specific Anthracycline Cancer Drugs through Disruption of the Circadian Pacemaker
Authors:
- Yumeng WangYWYumeng Wang
- Sabina Y. van der ZandenSZSabina Y. van der Zanden
- Suzanne van LeerdamSuzanne van Leerdam
- Mayke M. H. TersteegMTMayke M. H. Tersteeg
- Anneke KasteleinAKAnneke Kastelein
- Stephan MichelSMStephan Michel
- Jacques NeefjesJNJacques Neefjes
- Johanna H. MeijerJMJohanna H. Meijer
- Tom DeboerTom Deboer
Open Access
Abstract
Cancer-related fatigue (CRF) is the most devastating long-term side effect of many cancer survivors that confounds the quality of life for months to years after treatment. However, the cause of CRF is poorly understood. As a result, cancer survivors, at best, receive psychological support. Chemotherapy has been shown to increase the risk of CRF. Here, we study therapy-induced fatigue in a non-tumor-bearing mouse model with three different topoisomerase II-poisoning cancer drugs. These drugs either induce DNA damage and/or chromatin damage. Shortly before and several weeks after treatment, running wheel activity and electroencephalographic sleep were recorded. We show that doxorubicin, combining DNA damage with chromatin damage, unlike aclarubicin or etoposide, induces sustained CRF in this model. Surprisingly, this was not related to changes in sleep. In contrast, our data indicate that the therapy-induced CRF is associated with a disrupted circadian clock. The data suggest that CRF is probably a circadian clock disorder that influences the quality of waking and that the development of CRF depends on the type of chemotherapy provided. These findings could have implications for selecting and improving chemotherapy for the treatment of cancer in order to prevent the development of CRF.Keywords
Funding Information
- Dutch Cancer Society KWF (11356)
This publication has 42 references indexed in Scilit:
- Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicinNature Communications, 2013
- Doxorubicin Enhances Nucleosome Turnover around PromotersCurrent Biology, 2013
- The Relationship Between Symptom Severity and Symptom Interference, Education, Age, Marital Status, and Type of Chemotherapy Treatment in Israeli Women With Early-Stage Breast CancerOncology Nursing Forum, 2010
- Targeting DNA topoisomerase II in cancer chemotherapyNature Reviews Cancer, 2009
- Short light–dark cycles affect sleep in miceEuropean Journal of Neuroscience, 2007
- Cancer-Related Fatigue: The Scale of the ProblemThe Oncologist, 2007
- The course of severe fatigue in disease‐free breast cancer patients: a longitudinal studyPsycho-Oncology, 2006
- Fatigue in long‐term breast carcinoma survivorsCancer, 2006
- Fatique Patterns Observed in Patients Receiving Chemotherapy and RadiotherapyCancer Investigation, 2000
- Precision of circadian wake and activity onset timing in the mouseJournal of Comparative Physiology A, 1986